COOPER COMPANIES, INC. (COO) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does COOPER COMPANIES, INC. Do?
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California. COOPER COMPANIES, INC. (COO) is classified as a large-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Albert G. White and employs approximately 14,000 people, headquartered in Pleasanton, California. With a market capitalization of $13.9B, COO is one of the prominent companies in the Healthcare sector.
COOPER COMPANIES, INC. (COO) Stock Rating — Reduce (April 2026)
As of April 2026, COOPER COMPANIES, INC. receives a Reduce rating with a composite score of 40.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.COO ranks #2,774 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, COOPER COMPANIES, INC. ranks #381 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
COO Stock Price and 52-Week Range
COOPER COMPANIES, INC. (COO) currently trades at $71.30. The stock lost $0.16 (0.2%) in the most recent trading session. The 52-week high for COO is $89.83, which means the stock is currently trading -20.6% from its annual peak. The 52-week low is $61.77, putting the stock 15.4% above its annual trough. Recent trading volume was 1.5M shares, reflecting moderate market activity.
Is COO Overvalued or Undervalued? — Valuation Analysis
COOPER COMPANIES, INC. (COO) carries a value factor score of 45/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 32.25x, compared to the Healthcare sector average of 23.63x — a premium of 36%. The price-to-book ratio stands at 1.63x, versus the sector average of 2.75x. The price-to-sales ratio is 3.32x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, COO trades at 17.75x EV/EBITDA, versus 6.34x for the sector.
Overall, COO's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
COOPER COMPANIES, INC. Profitability — ROE, Margins, and Quality Score
COOPER COMPANIES, INC. (COO) earns a quality factor score of 45/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 5.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 3.4% versus the sector average of -33.1%.
On a margin basis, COOPER COMPANIES, INC. reports gross margins of 66.8%, compared to 71.5% for the sector. The operating margin is 18.7% (sector: -66.1%). Net profit margin stands at 10.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 37.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
COO Debt, Balance Sheet, and Financial Health
COOPER COMPANIES, INC. has a debt-to-equity ratio of 49.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.34x, suggesting adequate working capital coverage. Cash and equivalents stand at $111M.
COO has a beta of 0.89, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for COOPER COMPANIES, INC. is 70/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.
COOPER COMPANIES, INC. Revenue and Earnings History — Quarterly Trend
In TTM 2026, COOPER COMPANIES, INC. reported revenue of $4.09B and earnings per share (EPS) of $0.67. Net income for the quarter was $422M. Gross margin was 66.8%. Operating income came in at $766M.
In Q1 2026, COOPER COMPANIES, INC. reported revenue of $1.02B and earnings per share (EPS) of $0.67. Net income for the quarter was $131M. Gross margin was 67.9%. Revenue grew 37.2% year-over-year compared to Q1 2025. Operating income came in at $213M.
In FY 2025, COOPER COMPANIES, INC. reported revenue of $4.09B and earnings per share (EPS) of $1.88. Net income for the quarter was $375M. Gross margin was 65.5%. Revenue grew 5.1% year-over-year compared to FY 2024. Operating income came in at $683M.
In Q3 2025, COOPER COMPANIES, INC. reported revenue of $1.06B and earnings per share (EPS) of $0.49. Net income for the quarter was $98M. Gross margin was 65.3%. Revenue grew 5.7% year-over-year compared to Q3 2024. Operating income came in at $176M.
Over the past 8 quarters, COOPER COMPANIES, INC. has demonstrated a growth trajectory, with revenue expanding from $747M to $4.09B. Investors analyzing COO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
COO Dividend Yield and Income Analysis
COOPER COMPANIES, INC. (COO) does not currently pay a dividend. This is common among growth-oriented companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
COO Momentum and Technical Analysis Profile
COOPER COMPANIES, INC. (COO) has a momentum factor score of 38/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 23/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 15/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
COO vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, COOPER COMPANIES, INC. (COO) ranks #381 out of 838 stocks based on the Blank Capital composite score. This places COO in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing COO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full COO vs S&P 500 (SPY) comparison to assess how COOPER COMPANIES, INC. stacks up against the broader market across all factor dimensions.
COO Next Earnings Date
No upcoming earnings date has been announced for COOPER COMPANIES, INC. (COO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy COO? — Investment Thesis Summary
The quantitative profile for COOPER COMPANIES, INC. suggests caution. Momentum is weak at 38/100, a headwind for near-term performance. Low volatility (stability score 70/100) reduces downside risk.
In summary, COOPER COMPANIES, INC. (COO) earns a Reduce rating with a composite score of 40.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on COO stock.
Related Resources for COO Investors
Explore more research and tools: COO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare COO head-to-head with peers: COO vs AZN, COO vs SLGL, COO vs VMD.